Novartis Buys Excellergy for $2B, Anthropic Vs. Pentagon, The Mansion Section | Diet TBPN

Overview

This episode dives into Novartis' $2 billion acquisition of Xcellergy, the evolving role of AI in pharmaceutical innovation, Anthropic's legal battle with the Pentagon, and the latest developments in AI models and pricing. The hosts also touch on luxury real estate and quirky personal anecdotes.

Notable Quotes

- If there's a comma in the wrong place, the FDA can send it back to you and say, 'There's an error.' You're back at the end of the line. – John Coogan, on the meticulous nature of FDA filings.

- The CEO, Todd Zavodnik, joined in 2025, sells the company in less than a year, and he's seen the story twice before. Clearly a great operator. – John Coogan, on Xcellergy's leadership and rapid success.

- These models are getting incredibly powerful. You need to contain them and think about safety. You need to lock it in a box—it cannot be allowed to run free. – John Coogan, using capybaras as a metaphor for AI model control.

💊 Novartis Acquires Xcellergy for $2 Billion

- Novartis, a $300 billion pharmaceutical giant, acquired Xcellergy, a five-year-old biotech company, for $2 billion.

- Xcellergy's lead program, EXL111, targets IgE molecules to improve allergy treatments, aiming for faster action, deeper impact, and longer-lasting effects.

- The acquisition aligns with Novartis' strategy to extend its allergy drug portfolio as patents for its blockbuster drug Zolair near expiration.

- CEO Todd Zavodnik's track record of billion-dollar exits highlights the importance of experienced leadership in biotech success.

🤖 AI's Role in Pharma Innovation

- AI is accelerating clinical trials and streamlining FDA filings by automating tasks like document review and data compilation.

- John Coogan shared how Python scripts were used to optimize FDA applications, showcasing AI's potential for incremental efficiency gains.

- Pharma companies like Novo Nordisk are leveraging AI agents to reduce trial timelines, signaling broader adoption of machine learning in the industry.

- Jordi Hays noted that AI narratives in pharma feel more credible compared to other industries due to tangible results.

🛡️ Anthropic vs. Pentagon: Legal and IPO Updates

- Anthropic scored a legal win against the Pentagon's supply chain risk designation, with the court finding the government's actions likely unlawful.

- The company is reportedly preparing for an IPO as early as Q4, aiming for a $60 billion valuation.

- John Coogan highlighted the broader implications of Anthropic's legal victory for corporate freedoms and AI innovation.

📈 AI Model Pricing and Capabilities

- Anthropic's new AI model, Mythos, promises significant advancements in coding, reasoning, and cybersecurity, but comes with higher operational costs.

- Subscription-based pricing is becoming the norm, with businesses optimizing usage across global teams to manage costs.

- Tyler discussed the compute crunch and the economic rationale behind rising AI model prices, emphasizing the growing demand for advanced capabilities.

🏡 Luxury Real Estate and Personal Anecdotes

- Billionaire Barry Diller purchased JFK's favorite New York penthouse for $11 million, a storied property with ties to the Kennedy family.

- The hosts shared quirky aspirations, like building homes around personal passions—whether bars, movie theaters, or wave pools.

- John Coogan humorously suggested getting lost skiing to end up at Healy's Bar, a custom-built $800,000 ski-in bar in Lake Tahoe.